Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?

详细信息    查看全文

• 作者：Maya Basu ; Aswini Balachandran ; Jonathan Duckett
• 关键词：Afferent function ; Mirabegron ; Urodynamics
• 刊名：International Urogynecology Journal
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：27
• 期：3
• 页码：427-431
• 全文大小：293 KB
• 参考文献：1.Wuest M, Eichhorn B, Grimm M, Wirth M, Ravens U, Kaumann A (2009) Catecholamines relax detrusor through beta-2 adrenoreceptors in mouse and beta-3 adrenoreceptors in man. J Pharmacol Exp Ther 328:213–222CrossRef PubMed
  2.Michel M, Cernecka H, Ochodnicky P (2011) Desirable properties of β3-adrenoreceptor agonists: implications for the selection of drug development candidates. Eur J Pharmacol 657:1–3CrossRef PubMed
  3.Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O (2007) Effect of ( R )-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta-3-adrenoreceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647CrossRef PubMed
  4.Kanie S, Otsuka A, Yoshikawa S, Morimoto T, Hareyama N, Okazaki S, Kobayashi R, Hasebe K, Nakao K, Hayashi R, Mochizuki H, Matsumoto R, Ozono S (2012) Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips. Urology 79:744.e1-7CrossRef PubMed
  5.Chapple C, Khullar V, Nitti VW et al (2015) Efficacy of the β3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials. Eur Urol 67:11–14CrossRef PubMed
  6.Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K (2014) Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. doi:10.​1002/​nau.​22645
  7.Abrams P, Kelleher C, Staskin D et al (2015) Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). Eur Urol 67:577–588CrossRef PubMed
  8.Malone-Lee J, Henshaw D, Cummings K (2003) Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int 92:415–417CrossRef PubMed
  9.Malone-Lee J, Al-Buheissi S (2009) Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 103:931–937CrossRef PubMed
  10.Nitti V, Rovner E, Bavendam T (2010) Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the finding of detrusor overactivity. BJU Int 105:1268–1275CrossRef PubMed
  11.Svalø J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, Bouchelouche P (2013) The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol 699:101–105CrossRef PubMed
  12.Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ (2010) Effects of CL316,243, a beta-3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 29:771–776CrossRef PubMed
  13.Aizawa N, Homma Y, Igawa Y (2012) Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol 62:1165–1173CrossRef PubMed
  14.Birder L, Nealen M, Kiss S et al (2002) Beta-adrenoreceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci 22:8063–8070PubMed
  15.Kanai A, Wyndaele J, Andersson K et al (2011) Researching bladder afferents- determining the effects of (3) adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn 30(5):684–691CrossRef PubMed
  16.Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor--which is the main mechanism of action? Eur Urol 43:1–5CrossRef PubMed
  17.Aizawa N, Igawa Y, Nishizawa O, Wyndaele J (2010) Effects of CL316,243, a beta-3-adrenoreceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 229:771–776
  
• 作者单位：Maya Basu (1)
  Aswini Balachandran (1)
  Jonathan Duckett (1)
  
  1. Department of Urogynaecology, Medway Maritime Hospital, Windmill Road,, Gillingham, Kent, ME7 5NY, UK
  
• 刊物主题：Gynecology; Urology/Andrology;
• 出版者：Springer London
• ISSN：1433-3023

文摘

Introduction and hypothesis The aim of this study was to evaluate for any association between pretreatment cystometry results and outcome of treatment with mirabegron in women with overactive bladder (OAB) symptoms.